Search research articles
Contact Us
Filters
Showing results (161-170 of 171) with videos related to
Page
of 18
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 10, 2011
A pilot study of MUC-1/CEA/TRICOM poxviral-based vaccine in patients with metastatic breast and ovarian cancer
Mahsa Mohebtash, Kwong-Yok Tsang, Ravi A Madan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 24, 2010
Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer
Yang-Min Ning, James L Gulley, Philip M Arlen, et al.
Oncoimmunology
|
September 14, 2016
TARP vaccination is associated with slowing in PSA velocity and decreasing tumor growth rates in patients with Stage D0 prostate cancer
Lauren V Wood, Antonio Fojo, Brenda D Roberson, et al.
The Oncologist
|
May 3, 2023
Flutamide With or Without PROSTVAC in Non-metastatic Castration Resistant (M0) Prostate Cancer
Ravi A Madan, Marijo Bilusic, Mark N Stein, et al.
Cancer Immunology, Immunotherapy : CII
|
November 6, 2009
Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer
James L Gulley, Philip M Arlen, Ravi A Madan, et al.
Journal for Immunotherapy of Cancer
|
March 5, 2021
Clinical and immunologic impact of short-course enzalutamide alone and with immunotherapy in non-metastatic castration sensitive prostate cancer
Ravi A Madan, Fatima Karzai, Renee N Donahue, et al.
Clinical Genitourinary Cancer
|
June 23, 2016
A Phase II Clinical Trial of TRC105 (Anti-Endoglin Antibody) in Adults With Advanced/Metastatic Urothelial Carcinoma
Andrea B Apolo, Fatima H Karzai, Jane B Trepel, et al.
Journal of Experimental & Clinical Cancer Research : CR
|
March 29, 2023
First-in-human phase 1 clinical trial of anti-core 1 O-glycans targeting monoclonal antibody NEO-201 in treatment-refractory solid tumors
Christopher B Cole, Maria Pia Morelli, Massimo Fantini, et al.
BJU International
|
January 19, 2016
Phase II trial of docetaxel, bevacizumab, lenalidomide and prednisone in patients with metastatic castration-resistant prostate cancer
Ravi A Madan, Fatima H Karzai, Yang-Min Ning, et al.
BJU International
|
September 24, 2020
Cabozantinib plus docetaxel and prednisone in metastatic castration-resistant prostate cancer
Ravi A Madan, Fatima H Karzai, Munjid Al Harthy, et al.
Page
of 18
Search research articles
Search
Showing results (161-170 of 171) with videos related to
Sort By:
Page
of 18
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 10, 2011
A pilot study of MUC-1/CEA/TRICOM poxviral-based vaccine in patients with metastatic breast and ovarian cancer
Mahsa Mohebtash, Kwong-Yok Tsang, Ravi A Madan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 24, 2010
Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer
Yang-Min Ning, James L Gulley, Philip M Arlen, et al.
Oncoimmunology
|
September 14, 2016
TARP vaccination is associated with slowing in PSA velocity and decreasing tumor growth rates in patients with Stage D0 prostate cancer
Lauren V Wood, Antonio Fojo, Brenda D Roberson, et al.
The Oncologist
|
May 3, 2023
Flutamide With or Without PROSTVAC in Non-metastatic Castration Resistant (M0) Prostate Cancer
Ravi A Madan, Marijo Bilusic, Mark N Stein, et al.
Cancer Immunology, Immunotherapy : CII
|
November 6, 2009
Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer
James L Gulley, Philip M Arlen, Ravi A Madan, et al.
Journal for Immunotherapy of Cancer
|
March 5, 2021
Clinical and immunologic impact of short-course enzalutamide alone and with immunotherapy in non-metastatic castration sensitive prostate cancer
Ravi A Madan, Fatima Karzai, Renee N Donahue, et al.
Clinical Genitourinary Cancer
|
June 23, 2016
A Phase II Clinical Trial of TRC105 (Anti-Endoglin Antibody) in Adults With Advanced/Metastatic Urothelial Carcinoma
Andrea B Apolo, Fatima H Karzai, Jane B Trepel, et al.
Journal of Experimental & Clinical Cancer Research : CR
|
March 29, 2023
First-in-human phase 1 clinical trial of anti-core 1 O-glycans targeting monoclonal antibody NEO-201 in treatment-refractory solid tumors
Christopher B Cole, Maria Pia Morelli, Massimo Fantini, et al.
BJU International
|
January 19, 2016
Phase II trial of docetaxel, bevacizumab, lenalidomide and prednisone in patients with metastatic castration-resistant prostate cancer
Ravi A Madan, Fatima H Karzai, Yang-Min Ning, et al.
BJU International
|
September 24, 2020
Cabozantinib plus docetaxel and prednisone in metastatic castration-resistant prostate cancer
Ravi A Madan, Fatima H Karzai, Munjid Al Harthy, et al.
Page
of 18